Budget impact analysis of the XEN®63 for the treatment of primary openangle glaucoma in Spain

Autor: J, Vila Arteaga, E, Gutierrez Díaz, J M, Martínez de la Casa, E, Millá Griñó, A, Asorey García, J, Salvador Alepuz, C, de Miguel González, R, Palomino Meneses, E, Uría Mundo

Publikováno v: Archivos de la Sociedad Española de Oftalmología (English Edition). 98:2-10

To evaluate the economic impact in Spain derived from the introduction of the XEN®63 implant as a surgical alternative in the management of primary open angle glaucoma (POAG) with or without cataract in refractory patients.A budget impact analysis w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c413d023a0ab4a0e983ba6fec2dccd2
https://doi.org/10.1016/j.oftale.2022.11.002

Budget impact analysis of the XEN®63 for the treatment of primary openangle glaucoma in Spain.

Autor: Vila Arteaga J; Hospital Universitario y Politécnico La Fe, Valencia, Spain. Electronic address: jorgevilaarteaga@gmail.com., Gutierrez Díaz E; Hospital Universitario 12 de Octubre, Madrid, Spain., Martínez de la Casa JM; Hospital Clínico San Carlos, Facultad de Medicina, Universidad Complutense, Madrid, Spain., Millá Griñó E; Hospital Clinic, Barcelona, Spain., Asorey García A; AbbVie Spain, S.L.U., Salvador Alepuz J; Former AbbVie employee., de Miguel González C; Market Access Area, Pharmalex Spain, Barcelona, Spain., Palomino Meneses R; Market Access Area, Pharmalex Spain, Barcelona, Spain., Uría Mundo E; Market Access Area, Pharmalex Spain, Barcelona, Spain.

Publikováno v: Archivos de la Sociedad Espanola de Oftalmologia [Arch Soc Esp Oftalmol (Engl Ed)] 2023 Jan; Vol. 98 (1), pp. 2-10. Date of Electronic Publication: 2022 Nov 24.